135701-67-6

Basic information

• Product Name: D-ARG-ARG-PRO-HYP-GLY-PHE-SER-D-PHE-LEU-ARG
• Synonyms: (D-ARG0,HYP3,D-PHE7,LEU8)-BRADYKININ;D-ARG-ARG-PRO-HYP-GLY-PHE-SER-D-PHE-LEU-ARG;D-ARG-[HYP3,D-PHE7,LEU8]-BRADYKININ;H-D-ARG-ARG-PRO-HYP-GLY-PHE-SER-D-PHE-LEU-ARG-OH;Aaphgpspla;bradykinin, Arg-Hyp(3)-Phe(7)-Leu(8)-;D-Arg-L-Arg-L-Pro-L-t4Hyp-Gly-L-Phe-L-Ser-D-Phe-L-Leu-L-Arg-OH;D-Arg-L-Arg-L-Pro-4-Hydroxy-L-Pro-Gly-L-Phe-L-Ser-D-Phe-L-Leu-L-Arg-OH
• CAS NO: 135701-67-6
• Molecular Formula: C57H89N19O13
• Molecular Weight: 1248.44
• Product Categories: Bradykinins;Peptides and Proteins;Peptides for Cell Biology
• Mol File: 135701-67-6.mol

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.48g/cm³
• Refractive Index: 1.676
• Storage Temp.: −20°C
• PKA: 3.34±0.10(Predicted)
• CAS DataBase Reference: D-ARG-ARG-PRO-HYP-GLY-PHE-SER-D-PHE-LEU-ARG(CAS DataBase Reference)
• NIST Chemistry Reference: D-ARG-ARG-PRO-HYP-GLY-PHE-SER-D-PHE-LEU-ARG(135701-67-6)
• EPA Substance Registry System: D-ARG-ARG-PRO-HYP-GLY-PHE-SER-D-PHE-LEU-ARG(135701-67-6)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 135701-67-6(Hazardous Substances Data)

Usage

Uses

As the provided materials do not specify any particular applications for D-ARG-ARG-PRO-HYP-GLY-PHE-SER-D-PHE-LEU-ARG, it is not possible to list its uses based on the given information. However, given the general functions of peptides, potential applications could include:
Used in Pharmaceutical Industry:
D-ARG-ARG-PRO-HYP-GLY-PHE-SER-D-PHE-LEU-ARG could be used as a therapeutic agent for [specific medical condition] due to its potential biological activities and interactions with cellular targets.
Used in Research and Development:
This peptide could be utilized as a research tool for studying [biological process or mechanism], contributing to a better understanding of its role and potential applications in various fields.

InChI:InChI=1/C57H89N19O13/c1-32(2)25-40(48(82)72-38(19-11-23-67-57(63)64)53(87)89-54(88)44-20-12-24-76(44)52(86)37(18-10-22-66-56(61)62)71-46(80)36(58)17-9-21-65-55(59)60)73-50(84)42(27-34-15-7-4-8-16-34)74-51(85)43(31-77)75-49(83)41(26-33-13-5-3-6-14-33)70-45(79)30-69-47(81)39-28-35(78)29-68-39/h3-8,13-16,32,35-44,68,77-78H,9-12,17-31,58H2,1-2H3,(H,69,81)(H,70,79)(H,71,80)(H,72,82)(H,73,84)(H,74,85)(H,75,83)(H4,59,60,65)(H4,61,62,66)(H4,63,64,67)/t35-,36-,37+,38+,39+,40+,41+,42-,43+,44+/m1/s1

Upstream product

• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 40350-83-2 (2S,4R)-4-(benzyloxy)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid 
• 4530-20-5 BOC-glycine 
• 13836-37-8 Boc-Arg(Tos)-OH 

Relevant articles and documents

Design, Synthesis, and in Vitro Activity of Bis(succinimido)hexane Peptide Heterodimers with Combined B1 and B2 Antagonist Activity

We have developed a series of peptide heterodimers based on the B2 antagonist D-Arg0-3,D-Phe7,Leu8>-BK (1) and the B1 antagonist Lys0-8,des-Arg9>-BK

A New Class of Bradykinin Antagonists: Synthesis and in Vitro Activity of Bissuccinimidoalkane Peptide Dimers

A systematic study on the dimerization of the bradykinin (BK) antagonist D-Arg0-Arg1-Pro2-Hyp3-Gly4-Phe5-Ser6-D-Phe7-Leu8-Arg9 has been performed.The first part of this study involved compounds wherein dimerization was carried out by sequentially replacing each amino acid with cysteine and cross-linking with bismaleimidohexane.The second part of this study utilized a series of bissuccinimidoalkane dimers wherein the intervening methylene chain was varied systematically from n = 2 to n = 12 while the point of dimerization was held constant at position 6.The biological activities of these dimers were then evaluated on BK-induced smooth muscle contraction in two different isolated tissue preparations: guinea pig ileum (GPI) and rat uterus (RU).Several of the dimeric BK antagonists displayed remarkable activites and long durations of action.In addition, dimerization at position 4, 7, 8, or 9 produced dimeric analogues with markedly reduced potency.Rank order of antagonist potency as a function of dimerization position is as follows: rat uterus, 6 > 5 > 0 > 2 > 1 >3 >> 4, 7, 8, 9; guinea pig ileum, 6 > 5 > 3 > 2 > 1 > 0 >> 4, 7, 8, 9.Evaluation of the linker length as represented by the number of methylene units indicated an optimal distance between the two monomeric peptides of six to eight methylene moieties.These studies also revealed that the carbon-chain length significantly affected the duration of action in vitro and resulted in partial agonism effects when n > 8.The optimum activity in vitro was achieved with dimerization at position 6 and n = 6 (designated herein as compound 25; alternatively, CP-0127).Similar effects in potency were also seen when the monomeric antagonist D-Arg0-Arg1-Pro2-Hyp3-Gly4-Phe5-Ser6-D-Phe7-Phe8-Arg9 (NPC-567) was dimerized using similar chemistry.These results suggest that the development of BK antagonists of significant therapeutic potential may be possible using a dimerization strategy that can overcome the heretofore limiting problems of potency and in vivo duration of action found with many of the BK antagonists in the literature.